Yes. Stem cell treatment can leave you with more pain, including soreness at an injection or cell-collection site. Worsening pain can also signal a complication, and it is not proof that the treatment is working. The FDA lists collection-site reactions, unwanted inflammation, immune responses, and infections among the risks of unapproved regenerative medicine products Important patient and consumer information about regenerative medicine therapies.
If you are considering treatment for chronic pain, or already feel worse after a procedure, the important questions are what was given, where it was given, and whether your symptoms need assessment now. A joint injection, an infusion into a vein, and a blood-forming stem cell transplant are different treatments. Their risks cannot be treated as interchangeable.

When worsening pain needs urgent care
Get urgent medical assessment for a hot, swollen, very painful joint, especially with fever or difficulty moving it. These can be signs of septic arthritis, an infection that can damage the joint if treatment is delayed. Do not wait for every symptom to appear before seeking help 000430.htm.
After a back procedure, new leg weakness or numbness, loss of bladder or bowel control, fever with back pain, or severe pain that prevents you from getting comfortable needs immediate medical attention 007425.htm.
Call your local emergency number for trouble breathing, swelling of the tongue or throat, or collapse after an injection or infusion. These may signal a severe allergic reaction. Do not wait for a reply from a clinic website or messaging service 000844.htm.
| What you notice | What to do |
|---|---|
| Mild soreness confined to the injection or collection site that is easing | Follow your written aftercare plan. Contact the treating team if the course differs from what they described. |
| Pain that keeps increasing, returns more strongly after improvement, or limits normal movement | Contact the treating clinician promptly rather than assuming it is a healing flare. |
| A hot, very swollen joint; fever with marked pain; new neurological symptoms; or breathing difficulty | Seek urgent or emergency care as described above. |
This table cannot diagnose the cause. Mild symptoms or the absence of fever do not establish that a treatment is safe.
Why pain can get worse
Injection and collection-site reactions
The treated area is not the only possible source of discomfort. If the procedure uses your own cells rather than donor cells, collecting tissue adds another procedure and another site to assess. FDA warnings include reactions at both collection and administration sites Important patient and consumer information about regenerative medicine therapies.
Inflammation, infection, or immune reactions
Unwanted inflammation and immune responses can follow unapproved cell treatment, and contamination during processing is another safety concern Important patient and consumer information about regenerative medicine therapies. With a knee joint injection, new heat, swelling, and severe pain need assessment rather than a guess about whether the cells are “activating” 000430.htm.
Procedure-related injury
Some risks come from the delivery procedure, not just the cells. MedlinePlus lists nerve-root injury, bleeding around the spine, and spinal infection as possible complications of epidural steroid injections. This is evidence about a different spinal procedure—not a stem cell complication rate—but it explains why new pain after a needle procedure should not automatically be blamed on tissue repair 007485.htm.
The original problem may remain
Pain after treatment does not, by itself, identify its cause. The original condition may still be responsible, a new problem may have developed, or the procedure may have caused a complication. A clinician needs to assess the timing, location, examination findings, and treatment record. Neither more pain nor less pain alone proves that cartilage, a disc, or a nerve has regenerated.
What studies actually tell us
Two safety reviews help explain why “How often does pain get worse?” has no single transferable answer. Both studied mesenchymal stromal cells, often called MSCs. They did not test every product sold as “stem cell treatment.”
A 2021 review pooled 62 clinical trials with 3,546 participants across roughly 20 disease types, using intravenous or local MSC delivery. Although its abstract calls the studies randomized trials, the results section identifies two as prospective nonrandomized studies. Compared with controls, pooled odds were higher for temporary fever (odds ratio 3.65, 95% confidence interval 2.05–6.49) and administration-site adverse events (odds ratio 1.98, 95% confidence interval 1.01–3.87). The site-event category included pain, swelling, bleeding, itching, and infection—not pain alone PMC8522073.
The same analysis did not find a statistically significant increase in death or infection compared with controls. That does not mean no deaths or infections occurred, or that a private-clinic product is safe. The review mixed diseases, cell sources, trial phases, and follow-up periods; its search ended on March 1, 2021 PMC8522073.
A 2024 review pooled 9 randomized trials with 540 adults with neurological conditions, using MSC-based treatment delivered into spinal fluid, sometimes alongside another delivery route. Musculoskeletal and connective-tissue adverse events were more frequent than in non-MSC control groups (risk ratio 1.61, 95% confidence interval 1.19–2.19). Reported study follow-up ranged from one day to 14 months, and the search ended on April 13, 2023 PMC11103979.
These are relative comparisons, not percentages of patients whose original pain condition worsened. Neither review gives your personal chance of a flare after a knee or disc injection. Small samples, differing products, and limited follow-up also leave uncertainty about uncommon or delayed harms PMC8522073 PMC11103979.
How long should a pain flare last?
There is no universal “normal flare” timetable for stem cell treatment. Ask the treating clinician what course they expect for the exact procedure and which changes require a call. Do not borrow recovery times from a different injection. For example, aftercare information for epidural steroids describes that treatment, not cell injections 007485.htm.
If pain is getting worse rather than easing, or new symptoms appear, seek assessment instead of waiting for an advertised recovery deadline. Pain severity, associated symptoms, and loss of function matter more than whether you are on a particular day after treatment.
Approval does not transfer between conditions
In the United States, the FDA’s patient warning states that regenerative medicine therapies have not been approved for chronic pain or orthopedic conditions such as osteoarthritis, disc disease, and knee or back pain Important patient and consumer information about regenerative medicine therapies.
That does not mean all cell therapies are unapproved. In December 2024, the FDA approved Ryoncil, a donor bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in children aged two months and older. That specific approval is not approval for joint or back pain Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. Blood-forming stem cell transplantation used in cancer care is also a separate treatment context, not a model for recovery after a pain-clinic injection Stem cell transplant.
In Japan’s regenerative medicine framework, provision plans govern care under the Act on the Safety of Regenerative Medicine. A submitted plan is not a declaration that a treatment will relieve your pain Index. Marketing approval of a regenerative medical product follows a separate framework. Ask about the exact product, indication, and approval conditions—not simply whether the clinic is registered 0003.
What to check before treatment
A pre-treatment assessment should include your medical conditions and medicines. Diabetes and immune-suppressing medicines are among the risk factors for septic arthritis 000430.htm. Discuss blood thinners and bleeding problems with the clinician performing an invasive procedure; do not stop prescribed medicines on your own 007485.htm.
Whether the proposal uses your own cells or donor-derived cells, ask these questions in writing:
- What exact cell product, tissue source, dose, and delivery route will be used? How are the cells processed and tested?
- Do the supporting studies match my diagnosis and disease stage? What were their control treatments, follow-up periods, and adverse events?
- Who assesses worsening pain, how do I reach them outside clinic hours, and where should I go for urgent care?
- What follow-up is available if I travel home after treatment in Japan?
When discussing stem cell treatment safety in Japan, ask for evidence about the proposed intervention rather than relying on the country or the word “registered.” FDA guidance also cautions that a ClinicalTrials.gov listing or FDA registration does not establish legal marketing status Important patient and consumer information about regenerative medicine therapies. A publication or registration is not, by itself, proof of pain relief.
Record your own before-and-after symptoms
Before treatment, write down where your usual pain is, what brings it on, and what you can normally do. Afterward, record the same details, plus any new symptoms. This gives the clinician a concrete comparison instead of only “I feel worse.”
For example, if stairs normally trigger your knee pain, note whether your usual stair use has become harder and whether pain now occurs at rest. Do not repeatedly provoke pain to test the treatment. Use a simple record:
- Date and time; pain location; a 0–10 pain score at rest and during usual, permitted activity.
- New swelling, redness, measured temperature, numbness, weakness, or changes in walking.
- Medicines taken and any changes in activity, alongside the treatment date and injection or infusion site.
Keep the discharge instructions and a record of the product, route, and treating facility. If care was provided under a Japanese provision plan, keep its number too; it does not replace your clinical treatment record. Follow the prescribed aftercare plan, and ask before starting extra medicines or changing existing ones. Do not delay urgent assessment to complete a diary.
The bottom line
Stem cell treatment can worsen pain, but pain alone cannot tell you whether the cause is temporary soreness, a complication, or the original condition. Do not accept worsening pain as proof of healing. Get new or escalating symptoms assessed, and judge treatment claims against evidence for your exact diagnosis and procedure.
Questions about arranging an appointment in Japan?
The Patient Support Team handles non-clinical enquiries and appointment coordination, not diagnosis or emergency care. Start with a general enquiry before sharing medical records.
This article provides general information, not a diagnosis or an individual treatment recommendation. If pain is worsening after treatment, contact a qualified clinician. For emergency symptoms, seek local emergency care.
References
- [1] FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies. Pain indications, safety warnings, and registration limits.
- [2] MedlinePlus, U.S. National Library of Medicine: Septic arthritis. Symptoms, risk factors, and the importance of prompt treatment.
- [3] MedlinePlus, U.S. National Library of Medicine: Low back pain—acute. Symptoms requiring immediate medical contact.
- [4] MedlinePlus, U.S. National Library of Medicine: Anaphylaxis. Severe allergic-reaction symptoms and emergency care.
- [5] MedlinePlus, U.S. National Library of Medicine: Epidural injections for back pain. Procedure-specific risks and aftercare; not evidence of cell-treatment efficacy or complication rates.
- [6] The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Research & Therapy, 2021. DOI: 10.1186/s13287-021-02609-x.
- [7] The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials. Stem Cell Research & Therapy, 2024. DOI: 10.1186/s13287-024-03748-7.
- [8] FDA: Approval of the first mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease. December 18, 2024.
- [9] National Cancer Institute: Stem Cell Transplants in Cancer Treatment.
- [10] Japan Ministry of Health, Labour and Welfare: Regenerative medicine.
- [11] Japan Pharmaceuticals and Medical Devices Agency: Regenerative Medical Products. Regulatory framework.




